Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Risicoverevening Policy Updates: Key Amendments for 2022-2025 Explained
On December 9, 2025, the Board of Directors of Zorginstituut Nederland (decision reference 2025027072) approved amendments to the Beleidsregels risicoverevening for 2022, 2023, 2024, and 2025. These changes, published in Staatscourant 2026 nr. 967 on January 19, 2026, correct te...
Characterizing Burnout in Health Professionals: Insights from the BEATS Study in Portugal
Burnout Health Professionals: Join the BEATS Study Call
Burnout health professionals in Portugal are invited to participate in the BEATS study, an initiative by the Portuguese Laboratory for Healthy Work Environments. Titled "B...
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investments and Trends
Latin America Pharma Growth is surging as a high-growth engine for Boehringer Ingelheim, with double-digit market expansions outpacing mature regions like Europe, according to D...